Currently, a single marker is often used to determine the predictive value of ICB and other cancer therapies (e.g., IHC of PD-L1 in anti-PD-1/PD-L1 therapy), but this method is insufficient for treatment decisions [92, 93]. This evidence concerns the gene CD274 and cancer.